Investment
Features
FeesSafety
Academy
More
Pluang+

Helen of Troy Q2 2027 earnings expected at $0.51/share with modest sales growth but profit pressure.

Company Fundamentals
06 Oct 2026
Rayan Ahmad
View Source
Neutral
Helen of Troy Q2 2027 earnings expected at $0.51/share with modest sales growth but profit pressure.

Helen of Troy is set to report its fiscal Q2 2027 earnings with an expected EPS of $0.51 and revenue around $442.3 million. While sales growth is anticipated due to strong brand performance and online initiatives, profit per share may decline because of softer demand and rising operating costs. Investors are watching closely as the company's shares recently hit new 52-week highs, reflecting optimism despite potential profit challenges. The upcoming report will reveal if Helen of Troy can maintain its positive financial outlook amid these mixed signals.

Helen of Troy's upcoming Q2 2027 earnings report provides context for consumer cyclical sector activity on Pluang. For readers following this sector, here is Pluang's market snapshot as of Oct 07, 2026 20:02 WIB: Of 112 priced Consumer Cyclical US stocks tradable on Pluang, 22 rose and 86 fell today. Notable movers include LEN at USD 75.52 with a 1-day change of -1.81% and Pluang order activity showing 77% Buy, YUM at USD 137.33 down 1.79% with 100% Sell orders, and RCL at USD 283.88 down 1.72% with 71% Sell orders. Typical hold times range from 67 to 132 days among these stocks.

More News

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...

Analyst Insights
Neutral
58 minutes ago
Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...

Market News
Bearish
1 hour ago
Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...

Analyst Insights
Bullish
1 hour ago
Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...

Analyst Insights
Bullish
2 hours ago
Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App